Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma

Abstract

Autologous SCT is a potentially curative procedure for patients with relapsed lymphoma (NHL). We analyzed the outcomes of 34 patients 60 years old, including eight patients 70 years old, who received BU and CY and SCT for NHL. Patients received BU 0.8 mg/kg i.v. (n=25) or 1 mg/kg p.o. (n=9) q 6 h × 14 doses and CY 60 mg/kg i.v. q day × 2 days. The median age was 66 (range, 60–78) years. Twenty-two patients had large cell, 10 follicular and two-mantle cell lymphoma. Fifteen patients were in a second or greater CR and 19 patients were in a PR. The median days to ANC >500/μl and platelet count >50 000/μl were 10 and 13 days respectively. The 100-day transplant-related mortality was 0%. Toxicities included interstitial lung disease (n=2), seizures in a patient with CNS lymphoma (n=1), mild veno-occlusive disease (n=2), and transient atrial fibrillation (n=4). With a median follow-up of 40 months, the 2-year overall survival and PFS were 67 and 54% respectively. BU/CY is a well-tolerated conditioning regimen for older patients with NHL. Age alone should not be used as an exclusion criterion for autologous SCT.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Bertini M, Boccomini C, Calvi R . The influence of advanced age on the treatment and prognosis of diffuse large cell lymphoma. Clin Lymphoma 2001; 1: 278–284.

    Article  CAS  PubMed  Google Scholar 

  2. Thieblemont C, Coiffier B . Lymphoma in older patients. J Clin Oncol 2007; 25: 1916–1923.

    Article  PubMed  Google Scholar 

  3. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Group d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005; 23: 4117–4126.

    Article  CAS  PubMed  Google Scholar 

  4. Haberman TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB et al. Rituximab-CHOP vs CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121–3127.

    Article  Google Scholar 

  5. Philip T, Armitage J, Spitzer G, Chauvin F, Jagannath S, Cahn JY . High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493–1498.

    Article  CAS  PubMed  Google Scholar 

  6. Philip T, Guglielmi C, Hagenbeck A, Somers R, van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's Lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  PubMed  Google Scholar 

  7. Buadi FK, Micallef IN, Ansell SM, Porrata LF, Dispenzieri A, Elliot MA et al. Autologous hematopoetic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 2006; 37: 1017–1022.

    Article  CAS  PubMed  Google Scholar 

  8. Jantunen E, Iala M, Juvonen E, Leppa S, Keskinen L, Vasala K et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant 2006; 34: 367–372.

    Article  Google Scholar 

  9. Bitran JD, Klein L, Link D, Kosirog-Glowacki J, Stewart C, Raack D et al. High-dose myeloablative therapy and autologous peripheral blood progenitor transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant 2003; 9: 383–388.

    Article  PubMed  Google Scholar 

  10. Jantunen E . Autologous stem cell transplantation beyond 60 years of age. Bone Marrow Transplant 2006; 38: 715–720.

    Article  CAS  PubMed  Google Scholar 

  11. Mileshkin LR, Seymour JF, Wolf MM, Januszewicz EH, Joyce P, Prince HM . Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leukemia and Lymphoma 2005; 46: 1575–1579.

    Article  CAS  PubMed  Google Scholar 

  12. Aggarwal C, Gupta S, Vaughan WP, Saylors GB, Salzman DE, Katz RO et al. Improved outcomes in intermediate-and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006; 12: 770–777. Bl.

    Article  CAS  PubMed  Google Scholar 

  13. Williams CB, Day SD, Reed MD, Copelan EA, Bechtel T, Leather HL et al. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biol Blood Marrow Transplant 2004; 10: 614–623.

    Article  CAS  PubMed  Google Scholar 

  14. Toor AA, Ayers J, Strupeck J, Parthasarathy M, Creech S, Rodriguez T et al. Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. Br J Hematol 2004; 124: 769–776.

    Article  Google Scholar 

  15. Kiss TL, Panzarella T, Messner HA, Meharchand J, Reddy V, Schimmer AD et al. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 31: 73–78.

    Article  CAS  PubMed  Google Scholar 

  16. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586.

    Article  PubMed  Google Scholar 

  17. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin′s Lymphomas: report of the jury. J Clin Oncol 1999; 17: 423–429.

    Article  CAS  PubMed  Google Scholar 

  18. Dey BR, Shaffer J, Yee AJ, McAfee S, Caron M, Power K et al. Comparison of outcomes after transplantation of peripheral blood stem cells vs bone marrow following an HLA identical nonmyeloablative conditioning regimen. Bone Marrow Transplant 2007; 40: 19–27.

    Article  CAS  PubMed  Google Scholar 

  19. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem cell support. New Engl J Med 2004; 350: 1287–1295.

    Article  CAS  PubMed  Google Scholar 

  20. Tiwari D, Gao F, Adkins DR, Vij R, DiPersio JF, Khoury HJ . Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplantation 2007; 40: 671–675.

    Article  CAS  PubMed  Google Scholar 

  21. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality than autologous transplantation. Bone Marrow Transplant 2003; 31: 667–678.

    Article  CAS  PubMed  Google Scholar 

  22. Snyder MJ, Johnson DB, Daly MB, Giguere JK, Harman GH, Harden EA et al. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study. Bone Marrow Transplant 1994; 14: 595–600.

    CAS  PubMed  Google Scholar 

  23. Horwitz S M, Horning SJ . Rituximab in stem cell transplantation for aggressive lymphoma. Curr Hematol Rep 2004; 3: 227–229.

    PubMed  Google Scholar 

  24. Fernandez HP, Escalon MP, Pereira D, Lazarus HM . Autotransplant conditioning regimens for aggressive lymphoma: are we on the right track? Bone Marrow Transplant 2007; 40: 505–512.

    Article  CAS  PubMed  Google Scholar 

  25. Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium Study. Biol Blood Marrow Transplant 2008; 14: 59–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Gopal AK, Gooley TA, Golden JB, Maloney DG, Bensinger WI, Petersdorf SH et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001; 27: 593–599.

    Article  CAS  PubMed  Google Scholar 

  27. Seshadri T, Kuruvilla J, Crump M, Keating A . Salvage therapy for relapsed/refractory diffuse large B cell lymphoma. Biol Blood Marrow Transplant 2008; 14: 259–267.

    Article  CAS  PubMed  Google Scholar 

  28. Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ . Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2007; 40: 919–924.

    Article  CAS  PubMed  Google Scholar 

  29. Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005; 35: 233–241.

    Article  CAS  PubMed  Google Scholar 

  30. Zver S, Zadnik V, Bunc M, Rogel P, Cerneic P, Kozelj M . Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol 2007; 85: 408–414.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to K K Ballen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yusuf, R., Dey, B., Yeap, B. et al. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 43, 37–42 (2009). https://doi.org/10.1038/bmt.2008.298

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.298

Keywords

This article is cited by

Search

Quick links